Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Keybanc Maintains Overweight on Harvard Bioscience, Lowers Price Target to $7

Keybanc analyst Paul Knight maintains Harvard Bioscience (NASDAQ:HBIO) with a Overweight and lowers the price target from $10 to $7.
byBenzinga Newsdesk
August 5, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Keybanc analyst Paul Knight maintains Harvard Bioscience (NASDAQ:HBIO) with a Overweight and lowers the price target from $10 to $7.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts